Premium
Basiliximab treatment of severe GVHD induced by donor lymphocyte infusion with interferon‐a
Author(s) -
Gu Ying,
Sun Jing,
Zhang Jianzhong
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12808
Subject(s) - basiliximab , medicine , donor lymphocyte infusion , complication , hematopoietic stem cell transplantation , graft versus host disease , lymphocyte , mucous membrane , erythema , erythema multiforme , transplantation , disease , immunology , dermatology , surgery , kidney transplantation
The development of acute graft‐versus‐host‐disease (GVHD) in recipients of donor lymphocyte infusion (DLI) is not rare and the complication is quite often fatal. We describe a severe skin GVHD patient who responded well to basiliximab. A 20‐year‐old male who received a hematopoietic stem cell transplantation at his age of 18. His fusion gene Aml1/Eto remained positive, so he was administered with DLI combined with interferon‐a (IFN‐a). Forty days after the therapy, he presented with severe skin rashes with multiple mucous membrane involvement. The skin and mucous lesions recovered after basiliximab treatment. So far, severe type of erythema multiforme in GVHD patients after DLI with IFN‐a injection is firstly reported here, together with a new alternative therapy.